Analyst Keay Nakae works at CHARDAN CAPITAL and is focused on the Healthcare sector with 188 price targets and ratings documented since 2015 spanning on 23 stocks. Analyst's average stock valuation to be materialised ratio is 42.87% with an average time for price targets to be met of 80.5 days.
Most recent stock forecast was given on PEAR, at 15-Nov-2022.
Keay Nakae best performing recommendations are on OCGN (OCUGEN, INC).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS, INC) at 8/2/2022. The price target of $200 was fulfilled within 1 day with a profit of $58.03 (40.87%) receiving and performance score of 408.75.
Average potential price target upside